← All assets

Subcutaneous · GLP-1 / glucagon dual

AZD9550

6 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.

Trials

6

Active

5

Recruiting

4

Completed

1

Sites

72

Countries

9

Endpoints

147

Composite endpoints

0

Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.

Development

Where the program stands

Trials by phase

Phase 1
3
Phase 1/2
1
Phase 2
2

Trials by status

Recruiting
4
Active, not recruiting
1
Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
65
Glycemic / diabetes
23
Other (unclassified)
22
Weight & body composition
19
MASH / liver
10
Other clinical outcomes
5
Cardiometabolic biomarkers
3

Most-measured metrics

Top 20 metrics across this asset's endpoints

Trials

Programs for this asset

Every trial for this molecule, with the same search, filters, and sort as the Trials tab.

6 of 6

Asset / PopulationKey I/E criterionEvidence
ASCENDA Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

AZD6234, AZD9550

Obesity / overweight

BMI ≥30Ph 2Active, not recruiting53May 2026
CONTEMPOA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

AZD6234, AZD9550

Obesity / overweight, Type 2 diabetes

BMI 27-39.9Ph 1/2Recruiting15Jan 2027
NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

AZD6234, AZD9550

Healthy volunteers, Hepatic impairment

BMI 18-42Ph 1Recruiting4Feb 2027
NCT07017179This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

AZD6234, AZD9550

Obesity / overweight

BMI ≥27Ph 2Recruiting3Aug 2026
NCT07013643A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

AZD6234, AZD9550

Healthy volunteers, Obesity / overweight

BMI 25-40Ph 1Recruiting2Dec 2026
NCT05848440A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

AZD9550

Healthy volunteers

BMI 18-30Ph 1Completed1Nov 2023